Jagsonpal Pharmaceuticals Limited — Q4 FY26 earnings call

Call held 28 Apr 2026

Management summary

Jagsonpal Pharma reported a strong recovery in Q4 FY26, with revenue growing 10% YoY to INR64 crores and PAT increasing 31% YoY to INR9 crores. For the full year, revenue grew 7% to INR287 crores, and net profit grew 19% to INR45 crores. The company announced a INR40 crores share buyback and a 200% dividend, reflecting confidence in its business model and commitment to shareholder value, while targeting 1.5x IPM growth for FY27 and beyond.

Highlights

  • Q4 FY26 Revenue grew 10% YoY to INR64 crores, indicating a strong recovery after two sluggish quarters.

  • Q4 FY26 PAT increased 31% YoY to INR9 crores, with PAT margin expanding to 14%.

  • FY26 net profit grew 19% to INR45 crores, outperforming revenue growth of 7%.

  • Cash position of over INR190 crores at year-end, reflecting strong financial discipline.

  • Announced INR40 crores share buyback and a 200% dividend, totaling INR66 crores in shareholder returns, signaling confidence in future cash flows and business acceleration.

Concerns

  • Gross margins for the full year FY26 saw a minor change, with Q4 showing a slight decline, attributed to product mix and timing issues.

  • The impact of new labor code was an exceptional item in Q3, affecting profitability for that quarter.

Key financials

2 periods

Q4 FY26

  • Revenue
    ₹64 Cr
    YoY +10%
  • EBITDA
    ₹11 Cr
    YoY +9%
  • EBITDA Margin
    16%
  • PAT
    ₹9 Cr
    YoY +31%
  • PAT Margin
    14%

FY26

  • Revenue
    ₹287 Cr
    YoY +7%
  • Operating EBITDA
    ₹61 Cr
  • Operating EBITDA Margin
    21%
  • Profits from Operations
    ₹45 Cr
    YoY +19%
  • Profits from Operations Margin
    16%
  • Gross Margin
    64.2%

What they filed

Q1 FY27: revenue up 7.9%, net profit up 18.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue75 74 59 76 74 −1%73 −1%64 +8%82 +8%
EBITDA16 16 9 14 16 +0%16 +0%11 +22%17 +21%
Net profit11 32 7 11 13 +18%11 −66%9 +29%13 +18%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Debt Debt disclosed
    We have close to INR190 crores of cash, and given our cash flows, we are very hopeful of recouping whatever we are paying out within the next 12 months. So technically we do have wherewithal to undertake an acquisition of up to INR400 crores with our own balance sheet. I think that is more than sufficient in the view of the board and I think they took a very pragmatic decision of not keeping too much cash in the company beyond what is potentially needed.
  • Dividend ₹4/share (special)
    Alongside this, the board has also recommended a 200% dividend including a one-time special dividend of 75%. This will result in a total payout of INR4 per share and an overall cash distribution of approx. INR26 crores.
  • Buyback ₹40 Cr Max ₹250/share
    On the buyback front, we have received shareholders' approval for the proposed INR40 crores buyback of up to 16 lakh equity shares at a price of INR250 per share. As mentioned earlier, the promoters shall not be participating in the same.
  • Liquidity Cash ₹190 Cr Strong balance sheet with a cash position of over INR190 crores at the end of the year or on 31st March.
    We also continue to maintain a strong balance sheet with a cash position of over INR190 crores.

Guidance & targets

Revenue

  • Revenue Growth Revenue · FY27 and beyond · High confidence 1.5x IPM growth (12-15%)
    And that is what our objective has been and obviously we are taking aspiration to beat it by 1.5x, which is 1.5 times more than the Indian Pharma Market growth... Currently the pharma industry is trending anywhere between 6%-7% to 8%-9%. So this is the window in which it is operating. And if I calculate 1.5x of that, it translates to anywhere between 12% to 15% right now.

    — Amrut Medhekar

Profitability

  • Return on Equity (ROE) Profitability · Ongoing · High confidence 18%

    Previously 16% → 18%

    This move is expected to have significant impact on our return ratios, with ROE increasing from approx. 16% to 18%, while ROCE shall improve from approx. 22% to close to 26%.

    — Nirav Vora

  • Return on Capital Employed (ROCE) Profitability · Ongoing · High confidence 26%

    Previously 22% → 26%

    — Nirav Vora

New Product Launches

  • Number of New Product Launches New Product Launches · FY27 · Medium confidence 9-10

    Previously 6 → 9-10

    So we had total of six new product launches and three SKUs, I mean the brand extensions. We intend to have similar number approximately 9 to 10 in this current year as well, in which half of it will be more of rejuvenating the older brands, the legacy brands that we have.

    — Amrut Medhekar

What to watch in Q1 FY27

Shareholder approval for dividend

Next quarter (forthcoming AGM)
Current Recommended by board
Target Approved in AGM

Why it matters

Confirmation of the 200% dividend payout, including the special dividend, is contingent on shareholder approval.

While the shareholder approval for the buyback was received on 27th April, the enhanced dividend is subject to the shareholder approval in the forthcoming AGM.

Risks & concerns

  • Cost pressures from packaging material and vendors

    medium

    Acknowledged cost pressures, especially on packaging material, but management believes the company's gross margins and allowed price increases will enable absorption.

    Having said that, clearly there are certain pressures on the cost front, especially packaging material. Clearly all the vendors are seeing cost increases and they obviously while they are carrying certain inventories, they will be looking to pass on some of the cost increases... I think our ability to take some of these cost increases are far superior and we are also allowed a 10% price increase.

    Management downplayed

  • Execution risk from over-aspirational product targets

    low

    Management acknowledges a potential risk of being over-aspirational on certain new products, but expresses confidence in internal operational excellence.

    One execution risk may be that we may go over-aspirational on certain products, but yet we want to give them a full try with our heart and soul so that we are able to achieve them. But we are not sure how those molecules will eventually emerge as a macro market. So I only see a macro risk happening for the organization.

    Management acknowledged

  • Impact of new labor code

    low

    The impact of the new labor code was an exceptional item taken in Q3, implying it was a one-time adjustment.

    The only exceptional item during the year was the impact of new labor code, which was taken in Q3, and overall the business continues to show meaningful improvement in core quality and profitability.

    Management acknowledged

Q&A highlights

8 direct
Structural vs. Seasonal Improvement in Q4 Direct
See, if you look at our portfolio, we hardly have products which are seasonal in nature. And therefore, what we see today is purely driven by operational strengthening, as well as some of the steps that we had taken in terms of our brand building and MR productivity improvement. So, all the growth is completely strategic and structurally made in favor of yields. And I don't see any of the seasonal impact there.

Clarifies that the strong Q4 performance is due to fundamental operational improvements, not temporary seasonal factors, indicating sustainable growth.

Asked by Deepesh from Maanya Finance

Confidence for further acceleration beyond current IPM outperformance Direct
We are saying even if we are not present in anti-obesity right now, our portfolio is strong enough to still beat the market and deliver a 1.5x the growth.

Management reiterates confidence in achieving 1.5x IPM growth, even without participation in high-growth segments like anti-obesity, due to the strength of their existing portfolio.

Asked by Deepesh from Maanya Finance

Rationale for distributing cash to shareholders vs. reinvesting for higher ROE Direct
Personally as a company, the board was of the view that keeping too much cash is also not productive, especially in the scenario of falling yields and also in a scenario wherein now we have access to bank finance to fund acquisitions. So if you look at our own balance sheet, you can easily believe that we can raise upwards of INR200 crores as fresh debt in the company.

Explains the capital allocation strategy, emphasizing that excess cash is unproductive and the company has sufficient access to debt for inorganic growth, justifying the buyback and dividend.

Asked by Deepesh from Maanya Finance

Impact of Middle East situation on raw material supply and cost Direct
Clearly from a demand perspective, there is no impact of whatever is happening on the Middle East... Having said that, clearly there are certain pressures on the cost front, especially packaging material. Clearly all the vendors are seeing cost increases... I believe pharmaceutical industry overall will be lesser impacted given that the gross margins in this industry are better than most other industries... our ability to take some of these cost increases are far superior and we are also allowed a 10% price increase.

Addresses a macro geopolitical risk, stating no demand impact but acknowledging cost pressures on packaging materials, which the company believes it can absorb due to healthy gross margins and allowed price increases.

Asked by Avnish Parman from Vaikaria

Structure of API cost increases and pass-through mechanism Direct
So typically the cost doesn't get as is transferred to a buyer or a client. So depending on the structure of the agreement, it is typically absorbed over a period of time and in a staggered fashion as per your purchase orders... the agreement also allows you time to absorb those increases over quarters. So it's not one quarter impact at all.

Provides insight into the supply chain and contract structure, indicating that cost increases are absorbed gradually and not immediately passed on, mitigating short-term margin impact.

Asked by Avnish Parman from Vaikaria

Revenue contribution and terms of trade for e-pharmacies Direct
Currently the number is almost insignificant for us to have any mention of this in terms of supplies to these online pharmacies... So currently we don't have per se very high volume or value contribution from these e-pharmacies.

Clarifies that e-pharmacies are not a significant channel for the company currently, indicating traditional sales channels remain dominant.

Asked by Madhur Rathi from Counter Cyclical Investments

Breakup of Q4 FY26 and FY26 growth into price, volume, and new products Direct
For the Indian Pharma Market, the volume growth has been approximately 1%, little less than 1%. New product has been little higher than 3%, it was around 3.1%. And price is little less than 5%, so it was around 4.8%. So sum total of this is around 8.5%... Now for Jagsonpal, the numbers reported are volume growth is 2%. New product is matching which is 3.2%. And our price growth is in the range of 6% to 7%. Sum total of this comes to 12%.

Provides a detailed breakdown of growth drivers for both the industry and Jagsonpal, showing Jagsonpal's outperformance in volume and price growth compared to the market.

Asked by Aditya Chheda from InCred Asset Management

MR efficiency and new products alignment Direct
Yes, yes, absolutely. So as I said, there is one upskilling workshop which has happened. There is a very good product and therapy training which was given to all the MRs. We are also looking at the talent improvement within the organization so that all the promotions also happen internally as a policy for the organization. While we try to blend with the external hiring in case, we are not able to find anybody internally for a new position.

Highlights ongoing efforts to improve MR productivity through training, talent development, and internal promotions, which are expected to drive growth without increasing headcount.

Asked by Hitaindra Pradhan from Maximal Capital

2 min read 6 chapters

Detailed narrative

Q4 FY26 Performance Overview

Jagsonpal Pharmaceuticals reported a strong recovery in Q4 FY26, with revenue growing 10% year-on-year to INR64 crores. This performance was driven by sharpened execution focus, particularly in MR productivity and retention. EBITDA grew 9% year-on-year to INR11 crores, maintaining stable margins at 16%, while PAT saw a sharper uptick, rising 31% year-on-year to INR9 crores, with a margin expansion to 14%.

FY26 Annual Performance and Market Outperformance

For the full fiscal year 2026, revenue grew modestly at around 7% to INR287 crores. Despite this, net profit grew significantly by 19% to INR45 crores, demonstrating strong financial discipline. The company outperformed the Indian Pharma Market (IPM) which grew 7-8% during Q4 and most of the year, with Jagsonpal's MAT growth at 12.2% (3.6% above market) and Q4 growth at 14.2% (against IPM's 10.5%).

Strategic Priorities and Growth Drivers

The company's strategic priorities include driving organic growth through enhanced MR productivity, sharper brand focus, and disciplined cost management. Key growth anchors were Gynaecology and Dermatology, which showed strong traction and improved prescription conversion. Management aims to achieve 1.5x IPM growth, translating to a 12-15% revenue growth target for FY27 and beyond, supported by new product launches and rejuvenation of older brands.

Capital Allocation and Shareholder Returns

Jagsonpal's board approved a INR40 crores share buyback at INR250 per share, with promoters not participating, expected to increase ROE from 16% to 18% and ROCE from 22% to 26%. Additionally, a 200% dividend was recommended, including a 75% special dividend, resulting in a total payout of INR4 per share or approximately INR26 crores. Combined, these initiatives represent a return of over INR66 crores to shareholders, reflecting confidence in the business model and cash generation.

Product Portfolio and New Launches

The company maintains a strong and balanced portfolio, with its top 10 brands contributing 58-60% of total sales, and nine of these ranked within the top five in their categories. In FY26, six new products and three SKUs were launched. For FY27, the company plans to launch 9-10 new products, with about half focused on rejuvenating existing legacy brands and the remainder in new product therapies within Gynaec, Ortho, and Derma.

Cost Management and Profitability

While Q4 gross margins saw a slight decline due to product mix, the full-year gross margin remained stable at 64.2%. Other expenses marginally increased by 30 basis points, primarily due to timing issues rather than structural changes. The company believes its strong gross margins (65-80% for branded companies) and ability to implement 10% price increases will help absorb cost pressures, particularly from packaging materials, without significantly impacting overall profitability.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls